Crossmark

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

Crossref DOI link: https://doi.org/10.1007/s40121-021-00496-6

Published Online: 2021-07-28

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bosaeed, Mohammad https://orcid.org/0000-0003-2971-5141
Mahmoud, Ebrahim

Alharbi, Ahmad

Altayib, Hadeel

Albayat, Hawra

Alharbi, Faisal

Ghalilah, Khalid

Al Arfaj, Abdulmajid

AlJishi, Jumana

Alarfaj, Abdullatif

Alqahtani, Hajar

Almutairi, Badriah M.

Almaghaslah, Manar

Alyahya, Nawaf M.

Bawazir, Abdullah

AlEisa, Saud

Alsaedy, Abdulrahman

Bouchama, Abderrezak

Alharbi, Malak

AlShamrani, Majid

Al Johani, Sameera

Aljeraisy, Majed

Alzahrani, Mohammed

Althaqafi, Abdulhakeem O.

Almarhabi, Hassan

Alotaibi, Athari

Alqahtani, Nasser

Arabi, Yaseen M.

Aldibasi, Omar S.

Alaskar, Ahmad
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04392973 at ClinicalTrials.gov

Documents that mention this clinical trial

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
https://doi.org/10.1007/s40121-021-00496-6
Funding

Funding for this research was provided by:

King Abdullah International Medical Research Center (RC20/174/R)
License Information

Text and Data Mining valid from 2021-07-28

Version of Record valid from 2021-07-28
More Information

Article History

Received: 3 June 2021

Accepted: 1 July 2021

First Online: 28 July 2021

Document is current

Any future updates will be listed below